My Path Melanoma – pro
My Path Melanoma – proMy Path Melanoma is a precision GEP test for difficult to diagnose melanocytic lesions. MyPath Melanoma gene expression profile (GEP) test is designed to provide objective information to aid in the diagnosis and to inform management decisions for patients with ambiguous melanocytic lesions. NCCN Cutaneoue Melanoma ME, B, 3, 2025 says: ” Consider the use of molecular testing for histologically equivocal lesions, as well as expert dermatopathology review.”.
M. Goldberg et al, Appropriate Statistical Methods to Assess Cross-study Diagnostic 23-Gene Expression Profile Test Performance for Cutaneous Melanocytic Neoplasms. The American Journal of Dermatopathology 46(12):p 833-838, December 2024.
Witkowski, A., Jarell, A. D., Ahmed, K. L., Siegel, J. J., Russell, B. H., Rogers, J. H., … Farberg, A. S. (2024). A clinical impact study of dermatologists’ use of diagnostic gene expression profile testing to guide patient management. Melanoma Management, 11(1). https://doi.org/10.2217/mmt-2023-0002
NCCN Cutaneous Melanoma 2025